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About 1 in 715 young adults is a survivor of childhood
malignancy, but these individuals are at increased risk of
considerable treatment-related morbidity or even mortality. A
recent study suggests that at least 60% have one or more
chronic health problems, whilst about 20% have three or more.
The principle goal of long-term follow-up (LTFU) of survivors is
to decrease the severity of late treatment complications by
performing appropriate surveillance to detect incipient toxicity,
and by facilitating timely diagnosis and management of
emerging or established late adverse effects. The content of
LTFU is dictated by the type and amount of treatment for the
malignancy, and has been defined in recent clinical guidelines.
Moreover, LTFU allows provision of survivor education,
psychosocial support and health promotion advice. However,
considerable variation exists in how LTFU is performed, with
several alternative models involving a range of professionals in
a variety of locations, depending on numerous clinical and
organisational factors. There is increasing utilisation of
multidisciplinary teams, and recognition of the importance of
effective transition strategies whereby care is transferred to
more age-appropriate providers, usually after a period of joint
care in adolescence. It is of paramount importance to ascertain
and meet the needs of survivors themselves.
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A
s the treatment of childhood malignancy has
continued to improve, with the overall 5-
year survival rate increasing from 25% for
children diagnosed in the 1960s to about 75% for
those diagnosed in the 1990s,1 the number of long-
term survivors has risen. More than 26 000 people
are alive in Britain after childhood malignancy,
and 1 in 715 of the current young adult population
is a survivor.1 2
However, survivors are at increased risk of
considerable morbidity and even mortality as a
result of late adverse effects of their previous
treatment. A cohort study of .2000 five-year
survivors from a large UK centre found that at
least 60% had one or more chronic health problems
and about 20% had three or more.3 More inten-
sively treated patients may develop late toxicity
even more frequently, as exemplified by survivors
of haemopoietic stem cell transplantation (HSCT),
of whom .90% had at least one late effect and
.70% had at least three.4 The range of late effects
encountered is very wide, affecting any organ,
system, tissue or function, with variable aetiology,
timing of onset, severity and complexity5 6 (fig 1),
and may encompass psychological problems
including difficulties with interpersonal relation-
ships and post-traumatic stress disorder.7 8
Increased late mortality has been documented in
the North American Childhood Cancer Survivor
Study, where .20 000 long-term survivors had a
standardised mortality ratio of 10.8, about 20% of
which was due to late side effects, especially
secondary malignancy, and pulmonary and cardiac
toxicity.9
With increasing recognition of the frequency
and importance of late adverse effects, long-term
follow-up (LTFU) has become an integral part of
the care of children and adolescents previously
treated for malignancy or who have undergone
HSCT. It is not difficult to identify examples of late
effects that may be diagnosed and managed in a
LTFU clinic with the expectation of definite
benefit, but it is less easy to be certain exactly
what impact LTFU programmes have on the
overall physical and psychosocial health of the
total population of long-term survivors.
Therefore, it is instructive to consider the
specific goals of LTFU. The principle aim is to
decrease the severity of late complications of
treatment, thereby hopefully reducing excess
morbidity or even mortality. This may be achieved
by undertaking appropriate surveillance to detect
incipient late effects, by diagnosing emerging or
established late effects promptly, or by facilitating
timely management of chronic toxicity.
Surveillance may include clinical assessment by
medical history and physical examination, the
performance of appropriate investigations, or both.
However, there are several other important roles of
LTFU, notably the delivery of ongoing health
education about the original malignancy, its
treatment and their consequences, including
potential late adverse effects (physical, psycholo-
gical and psychosocial), and the provision of
support and advice to help survivors deal with
these consequences. In addition, LTFU permits the
provision of relevant health promotion advice, and
may offer important opportunities for research
into late adverse effects.
Clinicians involved in LTFU agree that the
content of follow-up is dictated by the nature
(drugs, radiotherapy, etc) and amount (dose and
intensity) of treatment previously received.
Historically, these have been the most important
determinants of the frequency and type of late
Abbreviations: LTFU, long-term follow-up; HSCT,
haemopoietic stem cell transplantation
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effects, although there is increasing interest in the potential
importance of genetic predisposition.10 In the last 2 years, three
groups from the UK and the USA have produced guidelines for
the content of LTFU.6 11 12 However, these documents do not
attempt to deal with issues regarding the most appropriate
organisational model for performing LTFU, as this will vary
from centre to centre, and over time, depending on several
factors including local resources, expertise and interests, centre
size and regional geography.
Therefore, LTFU incorporates different strategies in different
centres, even within a single country. Indeed, given the
treatment-based approach to determining its content, LTFU
often varies considerably between different patient groups in
the same centre. However, there are common strands to LTFU
that are applicable to and potentially beneficial for all survivors,
particularly the provision of health education, psychosocial
support and health promotion advice. Strategies to meet the
variable additional needs of particular groups of survivors may
be best illustrated by a range of selected examples, although it
should be borne in mind that other approaches may be
applicable to each scenario described below.
Some patients (eg, those with low stage Wilms’ tumour) may
be cured of their malignancy by relatively simple treatment with
very little risk of long-term toxicity. Historically many such
patients have been discharged from follow-up, and contemporary
practice usually embraces a low intensity of LTFU. This may be
delivered in several different ways, but one suggested strategy is
regular (eg, every 2 years) postal or telephone contact.
Most children treated for acute lymphoblastic leukaemia
have received 2 or 3 years of combination chemotherapy, with a
moderate risk of causing late adverse effects, including a low
but definite risk of severe toxicity (eg, anthracycline-induced
cardiomyopathy). Most survivors of acute lymphoblastic
leukaemia probably require LTFU by an appropriately trained
or experienced individual, but this need not necessarily be a
paediatric oncologist or related specialist. Indeed ‘‘protocol-
driven’’ LTFU may be delivered by a nurse or a primary care
doctor in a variety of locations, ranging from the referring
paediatric oncology unit (or allied age-appropriate hospital
clinic) to primary care. Provision of appropriate information for
non-specialist carers (such as general practitioners) is impor-
tant to ensure that they are aware of the specific late effects
that may occur in particular patients, and may be facilitated by
the use of individualised patient-held records.
Some groups of survivors have greater LTFU needs as a result of
their initial diagnosis and its treatment (eg, survivors of brain
tumours), or because they have received more intensive treat-
ment (eg, HSCT). Most such patients require medically super-
vised LTFU, often involving considerable additional specialist
input (eg, from endocrinologists), usually hospital based, on a
regular (at least annual) basis. Finally, occasional patients who
have already developed a particular late effect (eg, pulmonary or
renal damage) or who are at high risk of an adverse outcome (eg,
speech delay or educational difficulties due to severe cisplatin-
induced hearing loss) may require specialist follow-up in a variety
of settings depending on local circumstances.
Others
   Metabolic (including pancreatic)
   Secondary malignancy
              Complexity
  Simple—bilateral high frequency 
hearing impairment due to cisplatin
     NB "simple" toxicity may still have 
severe consequences (eg speech 
impairment, educational difficulties)
  Complex—cardiotoxicity
     Anthracycline—induced 
cardiomyopathy    > congestive 
cardiac failure
     Radiotherapy induced "early onset" 
coronary artery disease
     More rarely
        Myocardial damage
        Valvular disease
        Pericarditis
 
Organs/systems/tissues
Central nervous system
Peripheral nervous system
Eyes
Ears
Craniofacial/dental
Endocrine system, including
  Hypothalamus/pituitary
  Thyroid
Reproductive system
  Gonads
  Uterus
Cardiovascular system
  Heart
  Vascular
Lungs
Gastrointestinal system, including
   Hepatobiliary system
Spleen
Breast
Urinary tract
  Kidneys
  Bladder/lower urinary tract
Skin
Musculoskeletal
  Muscular
  Bone, including spine
                   Severity
   Mild—dental caries after chemotherapy 
or cranial/facial radiotherapy
   Moderate—cataract after radiotherapy 
to a field including the eye
   Severe—pulmonary fibrosis due to 
carmustine
   Potentially life threatening—secondary 
malignancies due to radiotherapy or 
chemotherapy (especially alkylating 
agents or epipodophyllotoxins)
                   Aetiology
   Chemotherapy—glomerular or renal 
tubular impairment due to ifosfamide, 
cisplatin, carboplatin
   Radiotherapy—hypothyroidism
   Surgery—increased risk of encapsulated 
bacterial infection after splenectomy
   Supportive care drugs—nephrotoxicity 
due to amphotericin or aminoglycosides
   Multifactorial—haemorrhagic cystitis 
may be due to either (or both of):
      chemotherapy (ifosfamide or 
   cyclophosphamide)
      radiotherapy
      and may be precipitated by GvHD or
 viral infection in patients with HSCT
   Post HSCT—numerous factors may be 
relevant including chemotherapy, 
radiotherapy, chronic GvHD
             Timing of onset
   Early—nephrotoxicity due to ifosfamide 
(usually during or first year after treatment)
   Late—secondary malignancies (may occur 
decades after treatment)
 Late adverse effects
may include
Functions
   Quality of life
   Neuropsychological
   Growth
Figure 1 Late adverse effects in long-term survivors of childhood malignancy, with illustrative examples of the wide variety of manifestations and broad
range of aetiological factors, timing of onset, severity and complexity. GvHD, graft versus host disease; HSCT, haemopoietic stem cell transplantation.
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These examples illustrate the range of intensities of LTFU
that may be appropriate for different groups of survivors.
Although the different models of LTFU mentioned above have
been proposed previously,13 considerable heterogeneity in
provision remains, with a wide range of alternative yet
appropriate strategies. In several cases, there is probably no
right or wrong approach. What is important is that the strategy
implemented is capable of fulfilling the aims of LTFU and that
it allows the appropriate content of LTFU surveillance to be
provided. Recent evidence implies that it is not difficult to
identify the intensity of LTFU care needed by individual
patients.14 If the appropriate level of care is given, then the
issues of ‘‘who provides LTFU, where and how often’’ become
less critical, recognising that more than one different model
may be appropriate. Nevertheless, much more research is
required, with the aim of facilitating the development of
LTFU strategies that are widely applicable and demonstrably
effective.15
Pending such research, the approach proposed by the
National Institute for Clinical Excellence in ‘‘Improving out-
comes in children and young people with cancer’’16 involves a
LTFU multidisciplinary team, including a lead clinician with
expertise in LTFU (usually an oncologist, but not necessarily
paediatric), a specialist nurse, an endocrinologist, an appro-
priate allied health professional (eg social worker) and a
psychologist. Further, the guidance suggests that an appro-
priate ‘‘key worker’’ should be identified to provide information
and support for, and coordinate the care of, each patient.
Although not specified in the guidance, specialist nurses may
fulfil this role effectively in many cases.
It is important to recognise that LTFU will usually extend
well beyond childhood, and that transitional strategies should
be developed whereby adolescent survivors are transferred to
the care of a more age-appropriate provider (and environment)
at a defined age, usually after a period of joint care.17 Many of
the challenges associated with transition are relevant to the
care of adolescents with other chronic illnesses (eg, cystic
fibrosis) managed by paediatricians and therefore well docu-
mented.18 However, it is particularly important to avoid losing
long-term survivors of cancer to follow-up at this stage, as
many of the potentially more serious late effects may not
manifest until a decade after completion of treatment or even
later. For example, the cumulative incidence of secondary
malignancies continues to rise for at least 25 years,19 while
there is increasing awareness of the development of late
cardiotoxicity up to 20 years after anthracycline treatment in
previously asymptomatic patients.20
There are several barriers to optimal provision of LTFU,
including factors related to survivors themselves (eg, social or
cultural background) and their healthcare providers (eg,
attitudes and beliefs).21 One of the most important obstacles
is lack of knowledge, among both survivors and non-specialist
clinicians.22 It is salutary to acknowledge that provision of
information about their illness, its treatment and future health
risks was one of the most important needs highlighted by a
focus group of survivors.23
The same focus group also identified the need for strategies
to deal with everyday but difficult issues such as seeking
employment or obtaining insurance.23 In addition, a modified
Delphi panel of survivors highlighted the need for guidance in
developing self-advocacy skills and accessing sources of
support.24 However, there is an increasing amount of informa-
tion designed to meet the specific information needs of
individual survivors, such as the United Kingdom Children’s
Cancer Study Group’s After cure package, which is available as a
booklet and also accessible on the internet.25 It covers general
issues about cancer and its treatment, providing advice about
lifestyle, health promotion, education and employment,
disability, life insurance and mortgages, travel and vaccina-
tions, fertility and sexual function, and is appropriate for all
survivors. Specific inserts are available describing particular
aspects of late toxicity relevant to individual survivors on the
basis of their previous treatment. Finally, it provides informa-
tion about childhood cancer survivor groups and several
relevant websites. A further suggestion deriving from one of
the consensus views of a workshop of survivors is that care
should be patient led with support from a key worker.26 Hence,
there is increasing awareness of the importance of providing
information for survivors, as well as seeking and acting on their
views when developing future models of LTFU.22
Research will continue to have a central role in the evolution
of LTFU. For many years, paediatric oncologists have expended
much effort in intensifying treatment for poor prognosis
malignancies in an attempt to cure more children, while
remaining mindful of the need for reduced treatment strategies
that can maintain high cure rates with less late toxicity in good
prognosis malignancies.27 Indeed, there are several ongoing
randomised controlled trials with reduced treatment arms
(lower doses or dose intensity, or reduced duration).
Nevertheless, inevitably, the continued use of intensive treat-
ment will be associated with a pronounced frequency of
potentially severe late effects, although it is often many years
before the full effect is evident. It is vital to continue careful
prospective evaluation looking for previously unrecognised late
effects, especially after novel treatments, including newer
biological agents (eg, targeted protein kinase inhibitors).
Similarly, it is important to seek better understanding of risk
factors, including genetic predisposition, although the multi-
factorial aetiology of many late effects complicates preventive
strategies. However, research should play an equally important
part in developing effective LTFU strategies to meet the needs of
the ever-increasing population of survivors of childhood cancer.
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